← Eichor
Condition: Head And Neck Hnscc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Head And Neck Hnscc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 1/Phase 2 · 2 location(s) · Fundació Institut de Recerca de l'Hospital de la Santa Creu · NCT06648096Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The K
Phase 4 · 1 location(s) · OHSU Knight Cancer Institute · NCT07405086A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Car
Phase 1/Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05668858Study of CHS-114 in Participants With Advanced Solid Tumors
Phase 1 · 16 location(s) · Coherus Oncology, Inc. · NCT05635643Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Re
Phase 1 · 2 location(s) · University of California, Davis · NCT06211335Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT03406247A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemoth
NA · 1 location(s) · The Second Affiliated Hospital of Hainan Medical University · NCT07546383EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)
Phase 1/Phase 2 · 29 location(s) · Grey Wolf Therapeutics · NCT06923761A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 47 location(s) · Bristol-Myers Squibb · NCT04895709A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Phase 1 · 1 location(s) · West China Hospital · NCT07106827Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous
Phase 2 · 1 location(s) · Xiuping Ding · NCT07055841Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognosticat
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT06678724Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer
NA · 7 location(s) · Centre Henri Becquerel · NCT04528420A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck S
Phase 1 · 17 location(s) · Johnson & Johnson Enterprise Innovation Inc. · NCT07219212Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Phase 1 · 1 location(s) · BlueSky Immunotherapies GmbH · NCT06589609First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs
Phase 2 · 1 location(s) · Yale University · NCT07172256Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT05414032Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
Phase 3 · 8 location(s) · Centre Leon Berard · NCT06706401Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
Phase 2 · 7 location(s) · Zhejiang Provincial People's Hospital · NCT05446467Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
Phase 2 · 1 location(s) · Yuankai Shi · NCT04857164Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Phase 2 · 1 location(s) · Christopher Wilke · NCT02128906Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck
Phase 1 · 48 location(s) · AbbVie · NCT05005403Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Adv
Phase 3 · 1 location(s) · Beijing Tongren Hospital · NCT06102395Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cel
Phase 2 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07601737Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
NA · 1 location(s) · Grit Biotechnology · NCT06190275Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC
Phase 2 · 2 location(s) · West China Hospital · NCT07572864A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Phase 1 · 39 location(s) · SystImmune Inc. · NCT05983432
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.